EGFR and head and neck squamous cell carcinoma: Ten patients included in this study had CTCs positive for EGFR. EGFR is commonly up-regulated in head and neck cancers and this receptor has emerged as a key molecular target for anti-cancer therapies including the monoclonal antibody therapy Cetuximab licensed for the treatment of HNSCC [46].